antineoplastic agent (chemotherapeutic agent)
Jump to navigation
Jump to search
Adverse effects
- nearly all chemotherapeutic agents are associated with urticaria & morbilliform rash[1]
Notes
- manufacturers have total price control of cancer drugs
- DrugAbacus can help physicians calculate what a cancer drug should cost
- ASCO proposed experiments in outcomes-based pricing of cancer drugs[2]
More general terms
More specific terms
- 1-(2-choloroethyl)-3-(2,5-dioxo-3-piperidyl)-1-nitrosourea (PCNU)
- 2-chlorodeoxyadenosine (2-CdA) [cladribine] (Leustatin)
- 5-fluorouracil [5-FU] (Fluoroplex, Efudex, Adrucel, Carac)
- 6-mercaptopurine (Purinethol, 6-MP, Mecaleukin, Leukerin, Leupurin)
- abarelix (Plenaxis)
- abiraterone acetate (Zytiga)
- alitretinoin (Panretin)
- alkylating agent
- alkylating agent combination
- all-trans retinoic acid; tretinoin (Retin-A, Renova, Avita, Altreno, ATRA)
- amcenestrant
- antibiotic antineoplastic agent
- antimitotic agent; mitotic inhibitor (antineoplastic agent)
- antineoplastic combination (combination chemotherapy)
- antineoplastic endocrine agent
- antineoplastic enzyme inhibitor
- antineoplastic immunomodulator
- antineoplastic monoclonal antibody
- antineoplastic photosensitizing agent
- antineoplastic platinum complex; platinum-based chemotherapy
- antineoplastic tyrosine kinase inhibitor
- antineoplastic-adjuvant combination
- antineoplaton
- apalutamide (Erleada)
- arsenic trioxide; As2O3 (Trisenox)
- asparaginase (Elspar)
- azacitidine; 5-azacytidine (Vidaza, Onureg)
- Bacillus Calmette-Guerin (BCG, TheraCys, TICE, Pacis)
- belagenpumatucel-L (Lucanix)
- belinostat (Beleodaq)
- belzutifan (Welireg)
- bexarotene (Targretin)
- BMS-354825
- brentuximab vedotin (Adcetris)
- buserelin (Suprecur)
- cabazitaxel
- calaspargase pegol-mkn (Asparlas)
- capecitabine (Xeloda)
- cedazuridine
- cepharanthine
- checkpoint inhibitor; immune checkpoint inhibitor; PD-1/PD-L1 inhibitor
- clofarabine (Clolar)
- CMP-001
- cytosine arabinoside; cytarabine (Cytosar, ARA-C, HiDAC, Depocyt)
- decitabine or 5-aza-2'-deoxycytidine
- enzalutamide (Xtandi)
- epothilone
- eribulin mesylate (Halaven)
- flavopiridol
- floxuridine; fluorodeoxyurine; 2'-Deoxy-5-fluorouridine
- fludarabine (Fludara)
- GDC-0449
- gemcitabine (Gemzar)
- gilteritinib (Xospata)
- gp100:209-217(210 M) peptide vaccine
- idecabtagene vicleucel (Abecma)
- imetelstat (Rytelo)
- levamisole (Ergamisole)
- metyrosine (Demser)
- midostaurin (Rydapt)
- mifamurtide (Mepact)
- mitoxantrone (Novantrone, Mitozantrone)
- mycophenolate (Cellcept, Myfortic)
- nadofaragene firadenovec
- nelarabine (Arranon)
- nimustine (ACNU)
- nirogacestat (Ogsiveo)
- nocodazole
- nogapendekin alfa inbakicept-pmln (Anktiva)
- oblimersen (Bcl-2 antisense)
- omacetaxine mepesuccinate; homoharringtonine (Synribo)
- panobinostat (Farydak)
- pegaspargase (Oncaspar, PEG-L-asparaginase)
- pentostatin (Nipent, DCF, 2'deoxycoformycin)
- plerixafor (Mozobil)
- Polatuzumab Vedotin (POLIVY)
- pralatrexate (Folotyn)
- proxigermanium; propagermanium; Ge-132- carboxyethylgermanium sesquioxide; 2-carboxyethylgermasesquioxane
- rabacfosadine (Tanovea)
- radium Ra[223] dichloride (Xofigo)
- radium-223
- raltitrexed (Tomudex)
- ramucirumab (Cyramza)
- ricin
- salinomycin; salinomycinum (Coxistac)
- samarium [Sm-153] lexidronam
- sintilimab
- small inhibitory antineoplastic agent (ib drug)
- strontium chloride
- tafasitamab-cxix (Monjuvi)
- tagraxofusp (Elzonris)
- talimogene laherparepvec (Imlygic)
- tazemetostat (Taxverik)
- tebentafusp-tebn (Kimmtrak)
- testolactone (Teslac, Fludestrin)
- TG101348
- tipiracil
- tirapazamine (TPZ)
- tirbanibulin (Klisyri)
- tisagenlecleucel; CTL019 (Kymriah)
- topoisomerase inhibitor
- trabectedin (Yondelis)
- venetoclax (Venclexta)
- verdinexor (Laverdia-CA1)
Additional terms
Component of
References
- ↑ 1.0 1.1 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
- ↑ 2.0 2.1 American Society of Clinical Oncology (ASCO) Position Statement On Addressing the Affordability of Cancer Drugs. June 1, 2017 http://www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/documents/2017-ASCO-Position-Statement-Affordability-Cancer-Drugs.pdf